TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 24 hour postoperative opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: energy levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: live birth rates (LBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of postoperative CIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Visualization of tracheal structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual control during puncturing the trachea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Granulation and re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intake of energy-dense nutrient-poor foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Baseline binding capacity (Bmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma total glutathione (GSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk reduction in cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in whole blood omega-3 fatty acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean of the sums of the quiz scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean of the sums of the examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in total calorie consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease in total fat consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease in cholesterol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anastomotic stricture
Endpoint domain: Adverse events/effects
Primary endpoint: 30-s chair stand test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ODS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean depth of rectocele
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final outcomes judged as effective
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: symptomatic hypoglycaemia rates
Endpoint domain: Adverse events/effects
Primary endpoint: 24-hour energy expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleeping energy expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak plasma concentration of etizolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total area under the plasma concentration‐time curve of etizolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elimination half‐life of etizolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heroin craving scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid drug-seeking behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of desmopressin add-on therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 5-year locoregional tumor control rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of late-onset, hospital-acquired VAP
Endpoint domain: Adverse events/effects
Primary endpoint: Total ICU stay
Endpoint domain: Resource use
Primary endpoint: Ventilator circuit costs
Endpoint domain: Resource use
Primary endpoint: Driving eligibility (visual acuity 20/40 or better)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EBT (quantitative measurement of airway inflammation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound healing without signs of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average number of days of drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound complications rate
Endpoint domain: Adverse events/effects
Primary endpoint: Pulp extirpation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of successful attempts at sexual intercourse
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of erections
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Activity of the Gpx enzyme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjacent segment degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Material failure
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative clinical scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myointimal hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: sickness absence
Endpoint domain: Resource use
Primary endpoint: self-rated pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on Rapid Visual Information Processing task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attenuation of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: NEI-VFQ-25 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Endothelial function measured as flow‐mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentrations of high‐sensitivity C‐reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentrations of IL‐6 and TNF‐α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Regress of the Lekken's index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pain syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need in nonsteroidal anti‐inflammatory drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of eligible patients identified
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of accrual opportunities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ineligibility rate for protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: success rates (IGA 0 or 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of inflammatory/noninflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stability index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight-bearing symmetry improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fear of falling improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Waist-to-Height-ratio (WHtR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urogenital Distress Inventory‐6 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incontinence Impact on Quality of Life‐7 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eight-year event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: CNS relapses
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in SAD (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in glucose infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in metabolic clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average sleep per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alertness after on-call nights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum IgE levels to allergens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median VP% value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma NT-proBNP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychological Health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VSC level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque formation inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS and Likert scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial GLP-1 secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical parameter improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in LDL-cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of immune reactions
Endpoint domain: Adverse events/effects
Primary endpoint: additional heroin free day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: reduction in morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: number of contaminated grafts
Endpoint domain: Adverse events/effects
Primary endpoint: growth of bacteria from graft segments
Endpoint domain: Adverse events/effects
Primary endpoint: growth of bacteria from glove imprints
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of reoperation or epidural injection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients achieving overall CCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic venous thromboembolism or major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in Mini‐Mental State Examination (MMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in regional cerebral blood flow (rCBF) in the frontal lobe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to relapse of any mood episode
Endpoint domain: Mortality/survival
Primary endpoint: lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: H(2)O(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Activation area and intensity in primary auditory cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: posttreatment improvement of overall skin quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Postchallenge itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postchallenge redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear histamine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stable therapeutic INR achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients experiencing INR >= 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients having doses held
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CR assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mTBS of permanent teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mTBS of primary teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung function (FEV1/FVC reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: serum cotinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for type of leaflet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients achieving blood pressure and LDL cholesterol targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean predicted CHD risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of radiographic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality or BPD
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of subjects with severe systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of iron-deficiency anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Successful aspiration of ascitic fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-ocular pressure (IOP) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth of anesthesia measured by bispectral index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-mental state examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in gingival recession height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved performance on selective neurocognitive tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence of bacterial cystitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Questionnaire score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of qualified referrals generated
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Estimated cost per year of life gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Echographic vertical and horizontal cup diameter measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cup depth readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EASI50 achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plasma LH, PRL, T, and insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Aqueous humour levels of ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body clearance of lorazepam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total body clearance of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median absolute prediction error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of microfilaraemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of acute disease manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Symptoms on the SSQ-14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of symptoms of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of health service contact
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reported use of proactive support services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean peak plasma concentrations (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total systemic exposures (AUC(0‐24))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elimination half‐life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of fulfilled Rome criteria for constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rectosigmoid transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of chronic kidney disease (≥stage 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comfort mean score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean inflammatory lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean acne severity grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median length of stay in PACU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of new onset cardiac arrhythmia
Endpoint domain: Adverse events/effects
Primary endpoint: Patient pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of handling
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Conformance with measures for myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Conformance with measures for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical and bacteriologic failures
Endpoint domain: Adverse events/effects
Primary endpoint: Nephro- or ototoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Tendon healing improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Power Output (PO) during 4-km Time Trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Power Output (PO) during 16.1-km Time Trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-km Cycling Time Trial Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 16.1-km Cycling Time Trial Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receiving bisphosphonate therapy for osteoporosis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Undergoing bone mineral density testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Receiving appropriate care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: risk of acute kidney injury
Endpoint domain: Adverse events/effects
Primary endpoint: Identification of women at risk of poor dental health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistent middle ear effusion (MEE)
Endpoint domain: Adverse events/effects
Primary endpoint: EE exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Right orbito-inferior prefrontal activation during no-go condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Activation in superior and medial temporal cortices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pulmonary immunologic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ankle pROM increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10MWT increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2MWT increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood complement levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prostate cancer stage and grade migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy in diagnosing recurrent meniscal tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of MR imaging in detecting meniscal tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean concentrations of anti-HPV antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in total glucose exposure (AUE(0,24 h))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Abnormal wall motion scores on echocardiograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Abnormal myocardial perfusion scores on 99mTc-tetrofosmin images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Abnormal myocardial sympathetic nerve function scores on 123I-MIBG images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes